Later, Goi and his team defined EG-VEGF and its corresponding receptor PROKR2 as prognostic markers in colorectal carcinoma [34, 35] suggesting a common pathway with VEGF sustained by their finding regarding the enhancement of antitumor effects when it was simultaneously targeting VEGF and EG-VEGF [36]. The gene discussed is VEGFA; the disease is colorectal carcinoma.